Two cases of pathological complete response to neoadjuvant chemoradiation therapy in pancreatic cancer

Yoko Nishimura, Ryo Nishiyama, Minoru Kitago, Yohei Masugi, Akihisa Ueno, Koichi Aiura, Shigeyuki Kawachi, Miho Kawaida, Yuta Abe, Masahiro Shinoda, Osamu Itano, Akihiro Tanimoto, Michiie Sakamoto, Yuko Kitagawa

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.

Original languageEnglish
Pages (from-to)26-31
Number of pages6
JournalKeio Journal of Medicine
Issue number2
Publication statusPublished - 2015 Jun 6


  • Neoadjuvant chemoradiation therapy
  • Pancreatic ductal adenocarcinoma
  • Pathological complete response

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Two cases of pathological complete response to neoadjuvant chemoradiation therapy in pancreatic cancer'. Together they form a unique fingerprint.

Cite this